Accro BioScience
Business Services · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Building A1 Biobay No.218 Xinghu Street ...Phone Number
+86 51262626021Website
www.accro.com.cnRevenue
$52.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Accro BioScience
Accro Bioscience was established in late 2017 and raised exclusive series A investment from Morningside Ventures. The company's research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis, which are associated with major human diseases.Explore more
Popular SearchesAccro BioScience Co. LtdAccro BioScience Co LtdAccropeutics BioscienceSIC Code 87,873NAICS Code 54,541Show moreAccro BioScience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Accro BioScience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Accro BioScience had a recent Job posting/layoffs
Product Launch: Get notified when Accro BioScience launches new products
Check if Accro BioScience has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Accro BioScience recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Accro BioScience
Funding: Get notified immidiatlly once Accro BioScience has new funding data
Check out if Accro BioScience is spiking on competitors!
Accro BioScience, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Accro BioScience
Find more new buyers
Company Profile Activity
Activity Insights
Accro BioScience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Accro BioScience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Accro BioScience.
Accro BioScience financials insights
Gather financial insights about Accro BioScience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$50M
Accro BioScience Tech Stack
A closer look at the technologies used by Accro BioScience
See more technologies
Accro BioScience News & Media
Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases
Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis NEW YORK and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Accro...Accro Bioscience to Present Phase II Data of AC-201 for Plaque Psoriasis at the European Academy of Dermatology & Venereology Congress 2025 in Paris
NEW YORK and SUZHOU, China, Sept. 4, 2025 /PRNewswire/ -- Accro Bioscience (Accropeutics), a clinical-stage biotech company focused on molecular mechanisms of regulated cell death and related pathogenesis in human diseases, today announced that it will present results from a Phase II...Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis
Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12 AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuation Efficacy and safety findings from this Phase 2 trial support advancing AC-201 into Phase 3 development for plaque psoriasis. NEW YORK and SUZHOU, China, May 21, 2025 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited (Accropeutics), a clinical-stage biotech company focusedTYK2/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permission for Phase I
SUZHOU, China, May 25, 2023 /PRNewswire/ -- Accropeutics Bioscience announced that its oral small molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee (HREC) to launch a clinical phase I trial in Australia. The trial will be a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and food effects of AC-201 in healthy adults. AC-201 is a novel small molecule
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Accro BioScience
Sign Up For FreeTo access detailed company insights
Accro Bioscience was established in late 2017 and raised exclusive series A investment from Morningside Ventures. The company's research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis, which are associated with major human diseases.... Read More
